Review



clinical strain ss1  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    ATCC clinical strain ss1
    Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain <t>SS1</t> following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.
    Clinical Strain Ss1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 269 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical strain ss1/product/ATCC
    Average 95 stars, based on 269 article reviews
    clinical strain ss1 - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "In vitro study on anti- Helicobacter pylori effects of DL-3-n-butylphthalide-loaded silk fibroin nanoparticles"

    Article Title: In vitro study on anti- Helicobacter pylori effects of DL-3-n-butylphthalide-loaded silk fibroin nanoparticles

    Journal: Frontiers in Microbiology

    doi: 10.3389/fmicb.2025.1750216

    Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.
    Figure Legend Snippet: Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.

    Techniques Used: Inhibition

    Molecular mechanisms of drug action against H. pylori . (A) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in ATCC 700392. (B) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in SS1. (C–E) Effect of drug treatment on urease activity in ATCC 700392. (F–H) Effect of drug treatment on urease activity in SS1 ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group). (I) Drug-induced ultrastructural alterations in H. pylori SS1 observed by SEM (30.0 kx, 40.0 kx, 70.0 kx). CagA protein expression in H. pylori SS1 treated with (J) NBP and (K) NBP-NPs ( n =3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. con trol group).
    Figure Legend Snippet: Molecular mechanisms of drug action against H. pylori . (A) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in ATCC 700392. (B) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in SS1. (C–E) Effect of drug treatment on urease activity in ATCC 700392. (F–H) Effect of drug treatment on urease activity in SS1 ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group). (I) Drug-induced ultrastructural alterations in H. pylori SS1 observed by SEM (30.0 kx, 40.0 kx, 70.0 kx). CagA protein expression in H. pylori SS1 treated with (J) NBP and (K) NBP-NPs ( n =3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. con trol group).

    Techniques Used: Gene Expression, Activity Assay, Control, Expressing

    Metabolite analysis of H. pylori SS1 treated in vitro with NBP and its nanoparticles. (A) TIC of QC sample chromatogram. (B) TIC of bacterial metabolites. The vertical axis represents the normalized intensity offset index for each group. The three distinct colors correspond to the three different experimental groups. (C) PCA of bacterial metabolites. (D) PLS-DA of bacterial metabolites. (E) Venn diagram analysis of differential metabolites between the NBP group and the NBP-NPs group. (F) Volcano plot depicting differential metabolites in the NBP group versus the control. (G) Volcano plot depicting differential metabolites in the NBP-NPs group versus the control. Metabolites marked in red, green, and gray represent those that are significantly upregulated, downregulated, or show no significant change, respectively. (H) Clustered heatmap showing the metabolite profiles of the NBP group compared to the control. (I) Clustered heatmap showing the metabolite profiles of the NBP-NPs group compared to the control. The color bar represents the relative abundance level of metabolites, with gradients from blue (low) to red (high). (J) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP. (K) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP-NPs. The size of each circle corresponds to the number of metabolites mapped to the pathway, and the color depth reflects the significance of the enrichment.
    Figure Legend Snippet: Metabolite analysis of H. pylori SS1 treated in vitro with NBP and its nanoparticles. (A) TIC of QC sample chromatogram. (B) TIC of bacterial metabolites. The vertical axis represents the normalized intensity offset index for each group. The three distinct colors correspond to the three different experimental groups. (C) PCA of bacterial metabolites. (D) PLS-DA of bacterial metabolites. (E) Venn diagram analysis of differential metabolites between the NBP group and the NBP-NPs group. (F) Volcano plot depicting differential metabolites in the NBP group versus the control. (G) Volcano plot depicting differential metabolites in the NBP-NPs group versus the control. Metabolites marked in red, green, and gray represent those that are significantly upregulated, downregulated, or show no significant change, respectively. (H) Clustered heatmap showing the metabolite profiles of the NBP group compared to the control. (I) Clustered heatmap showing the metabolite profiles of the NBP-NPs group compared to the control. The color bar represents the relative abundance level of metabolites, with gradients from blue (low) to red (high). (J) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP. (K) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP-NPs. The size of each circle corresponds to the number of metabolites mapped to the pathway, and the color depth reflects the significance of the enrichment.

    Techniques Used: In Vitro, Control



    Similar Products

    clinical strain ss1  (ATCC)
    95
    ATCC clinical strain ss1
    Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain <t>SS1</t> following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.
    Clinical Strain Ss1, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical strain ss1/product/ATCC
    Average 95 stars, based on 1 article reviews
    clinical strain ss1 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    clinical s aureus strains  (ATCC)
    99
    ATCC clinical s aureus strains
    Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain <t>SS1</t> following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.
    Clinical S Aureus Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical s aureus strains/product/ATCC
    Average 99 stars, based on 1 article reviews
    clinical s aureus strains - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    clinical strain 2403  (ATCC)
    93
    ATCC clinical strain 2403
    Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical <t>strain</t> <t>2403</t> ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.
    Clinical Strain 2403, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical strain 2403/product/ATCC
    Average 93 stars, based on 1 article reviews
    clinical strain 2403 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    cosmetic creams 17 b cereus 49063 atcc clinical outbreak strain b cereus 14579 atcc food  (ATCC)
    90
    ATCC cosmetic creams 17 b cereus 49063 atcc clinical outbreak strain b cereus 14579 atcc food
    Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical <t>strain</t> <t>2403</t> ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.
    Cosmetic Creams 17 B Cereus 49063 Atcc Clinical Outbreak Strain B Cereus 14579 Atcc Food, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cosmetic creams 17 b cereus 49063 atcc clinical outbreak strain b cereus 14579 atcc food/product/ATCC
    Average 90 stars, based on 1 article reviews
    cosmetic creams 17 b cereus 49063 atcc clinical outbreak strain b cereus 14579 atcc food - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    clinical s pneumoniae strains  (ATCC)
    94
    ATCC clinical s pneumoniae strains
    Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical <t>strain</t> <t>2403</t> ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.
    Clinical S Pneumoniae Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/clinical s pneumoniae strains/product/ATCC
    Average 94 stars, based on 1 article reviews
    clinical s pneumoniae strains - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    pixantrone exposure clinical s aureus strains  (ATCC)
    99
    ATCC pixantrone exposure clinical s aureus strains
    Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical <t>strain</t> <t>2403</t> ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.
    Pixantrone Exposure Clinical S Aureus Strains, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pixantrone exposure clinical s aureus strains/product/ATCC
    Average 99 stars, based on 1 article reviews
    pixantrone exposure clinical s aureus strains - by Bioz Stars, 2026-02
    99/100 stars
    		  Buy from Supplier
    f nucleatum clinical strain 2256  (ATCC)
    97
    ATCC f nucleatum clinical strain 2256
    Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical <t>strain</t> <t>2403</t> ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.
    F Nucleatum Clinical Strain 2256, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/f nucleatum clinical strain 2256/product/ATCC
    Average 97 stars, based on 1 article reviews
    f nucleatum clinical strain 2256 - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.

    Journal: Frontiers in Microbiology

    Article Title: In vitro study on anti- Helicobacter pylori effects of DL-3-n-butylphthalide-loaded silk fibroin nanoparticles

    doi: 10.3389/fmicb.2025.1750216

    Figure Lengend Snippet: Inhibitory and bactericidal effects of NBP and NBP-NPs. (A) The colony morphology of H. pylori strains after treatment with various drug concentrations. (B) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP. (C) Bacterial growth inhibition kinetics of strain ATCC 700392 following treatment with NBP-NPs. (D) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP. (E) Bacterial growth inhibition kinetics of strain SS1 following treatment with NBP-NPs.

    Article Snippet: As shown in – , both NBP and NBP-NPs exhibited clear inhibitory effects on the standard strain ATCC 700392 and clinical strain SS1.

    Techniques: Inhibition

    Molecular mechanisms of drug action against H. pylori . (A) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in ATCC 700392. (B) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in SS1. (C–E) Effect of drug treatment on urease activity in ATCC 700392. (F–H) Effect of drug treatment on urease activity in SS1 ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group). (I) Drug-induced ultrastructural alterations in H. pylori SS1 observed by SEM (30.0 kx, 40.0 kx, 70.0 kx). CagA protein expression in H. pylori SS1 treated with (J) NBP and (K) NBP-NPs ( n =3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. con trol group).

    Journal: Frontiers in Microbiology

    Article Title: In vitro study on anti- Helicobacter pylori effects of DL-3-n-butylphthalide-loaded silk fibroin nanoparticles

    doi: 10.3389/fmicb.2025.1750216

    Figure Lengend Snippet: Molecular mechanisms of drug action against H. pylori . (A) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in ATCC 700392. (B) Impact of NBP and NBP-NPs treatment on virulence gene expression levels in SS1. (C–E) Effect of drug treatment on urease activity in ATCC 700392. (F–H) Effect of drug treatment on urease activity in SS1 ( n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. control group). (I) Drug-induced ultrastructural alterations in H. pylori SS1 observed by SEM (30.0 kx, 40.0 kx, 70.0 kx). CagA protein expression in H. pylori SS1 treated with (J) NBP and (K) NBP-NPs ( n =3, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 vs. con trol group).

    Article Snippet: As shown in – , both NBP and NBP-NPs exhibited clear inhibitory effects on the standard strain ATCC 700392 and clinical strain SS1.

    Techniques: Gene Expression, Activity Assay, Control, Expressing

    Metabolite analysis of H. pylori SS1 treated in vitro with NBP and its nanoparticles. (A) TIC of QC sample chromatogram. (B) TIC of bacterial metabolites. The vertical axis represents the normalized intensity offset index for each group. The three distinct colors correspond to the three different experimental groups. (C) PCA of bacterial metabolites. (D) PLS-DA of bacterial metabolites. (E) Venn diagram analysis of differential metabolites between the NBP group and the NBP-NPs group. (F) Volcano plot depicting differential metabolites in the NBP group versus the control. (G) Volcano plot depicting differential metabolites in the NBP-NPs group versus the control. Metabolites marked in red, green, and gray represent those that are significantly upregulated, downregulated, or show no significant change, respectively. (H) Clustered heatmap showing the metabolite profiles of the NBP group compared to the control. (I) Clustered heatmap showing the metabolite profiles of the NBP-NPs group compared to the control. The color bar represents the relative abundance level of metabolites, with gradients from blue (low) to red (high). (J) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP. (K) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP-NPs. The size of each circle corresponds to the number of metabolites mapped to the pathway, and the color depth reflects the significance of the enrichment.

    Journal: Frontiers in Microbiology

    Article Title: In vitro study on anti- Helicobacter pylori effects of DL-3-n-butylphthalide-loaded silk fibroin nanoparticles

    doi: 10.3389/fmicb.2025.1750216

    Figure Lengend Snippet: Metabolite analysis of H. pylori SS1 treated in vitro with NBP and its nanoparticles. (A) TIC of QC sample chromatogram. (B) TIC of bacterial metabolites. The vertical axis represents the normalized intensity offset index for each group. The three distinct colors correspond to the three different experimental groups. (C) PCA of bacterial metabolites. (D) PLS-DA of bacterial metabolites. (E) Venn diagram analysis of differential metabolites between the NBP group and the NBP-NPs group. (F) Volcano plot depicting differential metabolites in the NBP group versus the control. (G) Volcano plot depicting differential metabolites in the NBP-NPs group versus the control. Metabolites marked in red, green, and gray represent those that are significantly upregulated, downregulated, or show no significant change, respectively. (H) Clustered heatmap showing the metabolite profiles of the NBP group compared to the control. (I) Clustered heatmap showing the metabolite profiles of the NBP-NPs group compared to the control. The color bar represents the relative abundance level of metabolites, with gradients from blue (low) to red (high). (J) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP. (K) KEGG pathway enrichment analysis of metabolites from H. pylori SS1 after treatment with NBP-NPs. The size of each circle corresponds to the number of metabolites mapped to the pathway, and the color depth reflects the significance of the enrichment.

    Article Snippet: As shown in – , both NBP and NBP-NPs exhibited clear inhibitory effects on the standard strain ATCC 700392 and clinical strain SS1.

    Techniques: In Vitro, Control

    Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical strain 2403 ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.

    Journal: Microorganisms

    Article Title: Scorpion Venom-Derived Peptides: A New Weapon Against Carbapenem-Resistant Acinetobacter baumannii

    doi: 10.3390/microorganisms14010068

    Figure Lengend Snippet: Inhibition of A. baumannii growth by pantinin-1 and pantinin-2 through the broth microdilution method. Bacterial cells from an ATCC strain BAA-747 ( A ) and the clinical strain 2403 ( B ) were pantinin-1 (P1), pantinin-2 (P2), gentamicin, or colistin (CTR+). Untreated cells represented the negative control (CTR−). Data represent the mean ± SD. Dunnett’s multiple comparison test: ( A ) **** p -value < 0.001; *** p -value = 0.0005; ** p -value = 0.0077 and ns = not significant; ( B ) **** p -value < 0.0001; *** p -value = 0.0002; ** p -value < 0.0077 and ns = not significant.

    Article Snippet: The antibacterial activity of pantinins was evaluated by the broth microdilution method and kinetic time-kill assays (see for details) against bacterial cells from an ATCC strain BAA-747(A) and clinical strain 2403.

    Techniques: Inhibition, Negative Control, Comparison